We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red. The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The interactive Survival Scatter plot allows for the cutoff to be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Survival analysis". Under the Survival Scatter plot the p-score landscape is shown together with the difference in median between survival time for patients who have died with respect to high and low expression. This is intended to aid the user in exploring custom cutoffs.
Individual patient data is displayed in an interactive plot and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off).
EEF1B2 is prognostic, high expression is unfavourable in melanoma
Stage:
Survival analysis
Current cut off: Best expression cut offi
Based on the FPKM value of each gene, we classified the patients into two groups and examined their prognoses. In the analysis, we excluded genes with low expression, i.e., those with a median expression among samples less than FPKM 1. The prognosis of each group of patients was examined by Kaplan-Meier survival estimators, and the survival outcomes of the two groups were compared by log-rank tests. To choose the best FPKM cut-offs for grouping the patients most significantly, all FPKM values from the 20th to 80th percentiles were used to group the patients, significant differences in the survival outcomes of the groups were examined and the value yielding the lowest log-rank P value is selected.
: 108.75
Median expression: N/A
Median follow up time: N/A P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A 3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A 3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average FPKM
117.6
Number of samples
102
Samples
Sample
Description
FPKM
TCGA-EB-A41B-01A
76 years, female, white, stage:iic, alive, 291 days
350.3
TCGA-XV-A9VZ-01A
90 years, female, white, stage:ii, alive, 11 days
325.8
TCGA-ER-A42H-01A
77 years, male, white, dead, 426 days
319.7
TCGA-D9-A4Z3-01A
73 years, female, white, stage:iiic, alive, 505 days
306.5
TCGA-ER-A2NF-01A
53 years, male, white, stage:iiib, dead, 877 days
257.5
TCGA-EB-A5UM-01A
48 years, female, white, stage:iic, alive, 779 days
252.1
TCGA-GF-A769-01A
39 years, male, white, stage:iic, dead, 1070 days
248.7
TCGA-ER-A19T-01A
51 years, male, white, stage:iv, dead, 270 days
247.6
TCGA-GN-A263-01A
24 years, male, white, stage:iv, dead, 467 days
224.2
TCGA-BF-A5EP-01A
75 years, female, white, stage:iiic, alive, 335 days
216.4
TCGA-EB-A82B-01A
58 years, female, asian, stage:iii, alive, 390 days
188.3
TCGA-BF-AAP8-01A
58 years, male, white, stage:iic, alive, 447 days
186.3
TCGA-ER-A19K-01A
79 years, female, white, stage:iic, dead, 469 days
177.8
TCGA-BF-AAP2-01A
62 years, male, white, stage:iib, alive, 405 days
177.4
TCGA-EB-A82C-01A
70 years, female, asian, stage:iic, alive, 17 days
173.9
TCGA-XV-AAZV-01A
56 years, female, white, stage:ii, alive, 412 days
172.0
TCGA-XV-A9W2-01A
81 years, male, white, stage:i, alive, 417 days
171.7
TCGA-EB-A5SE-01A
73 years, male, white, stage:iib, dead, 401 days
170.6
TCGA-EB-A85J-01A
66 years, female, white, stage:iib, alive, 360 days
168.5
TCGA-BF-AAOX-01A
83 years, male, white, stage:iic, alive, 444 days
162.3
TCGA-EB-A6QY-01A
71 years, male, white, stage:iic, alive, 382 days
156.5
TCGA-EB-A4XL-01A
56 years, female, white, stage:iic, alive, 777 days
148.3
TCGA-FR-A726-01A
90 years, male, white, stage:iic, dead, 305 days
138.8
TCGA-EB-A550-01A
75 years, female, white, stage:iic, dead, 264 days
138.5
TCGA-EB-A42Y-01A
73 years, female, asian, stage:iic, dead, 721 days
132.4
TCGA-BF-A1PV-01A
74 years, female, white, stage:iic, alive, 14 days
131.9
TCGA-GN-A8LN-01A
68 years, male, white, stage:iic, alive, 772 days
131.6
TCGA-EB-A5VU-01A
56 years, male, asian, stage:iiib, dead, 321 days
131.3
TCGA-ER-A196-01A
64 years, female, white, stage:iic, alive, 1785 days
130.3
TCGA-EB-A44N-01A
59 years, male, white, stage:iic, dead, 205 days
130.1
TCGA-BF-A5EQ-01A
63 years, male, white, stage:iic, alive, 323 days
125.1
TCGA-BF-AAOU-01A
73 years, female, white, stage:iic, alive, 476 days
124.5
TCGA-EB-A6QZ-01A
76 years, female, white, stage:iia, dead, 352 days
117.4
TCGA-EB-A4P0-01A
82 years, male, white, stage:iic, dead, 326 days
115.6
TCGA-EB-A51B-01A
53 years, male, white, stage:iic, alive, 931 days
115.5
TCGA-EB-A3XC-01A
74 years, male, white, stage:iic, alive, 650 days
115.0
TCGA-BF-A1PX-01A
56 years, male, white, stage:iiib, dead, 282 days
114.7
TCGA-BF-AAP1-01A
86 years, male, white, stage:iic, alive, 409 days
114.7
TCGA-EB-A24D-01A
72 years, male, white, stage:iiib, alive, 645 days
113.4
TCGA-GF-A2C7-01A
48 years, male, white, stage:iic, alive, 21 days
112.9
TCGA-XV-AAZW-01A
62 years, female, white, stage:ii, dead, 393 days
112.5
TCGA-EB-A44O-01A
69 years, male, white, stage:iib, alive, 81 days
111.6
TCGA-FR-A2OS-01A
49 years, female, white, stage:iic, dead, 368 days
111.6
TCGA-EB-A5FP-01A
65 years, female, white, stage:iv, dead, 454 days
110.9
TCGA-EB-A553-01A
62 years, male, white, stage:iic, alive, 226 days
109.5
TCGA-D9-A4Z2-01A
50 years, male, white, stage:iiic, dead, 190 days
108.8
TCGA-EB-A299-01A
63 years, male, white, stage:iia, alive, 378 days
108.7
TCGA-EB-A41A-01A
90 years, male, white, stage:iic, alive, 262 days
108.6
TCGA-EB-A24C-01A
56 years, male, white, alive, 632 days
108.3
TCGA-FR-A3R1-01A
69 years, male, white, stage:iic, alive, 685 days
108.0
TCGA-EB-A3XF-01A
57 years, male, white, stage:iic, alive, 278 days
105.6
TCGA-BF-A1PZ-01A
71 years, female, white, stage:iib, alive, 853 days
103.5
TCGA-IH-A3EA-01A
61 years, male, white, stage:iic, alive, 524 days
102.3
TCGA-EB-A3XE-01A
77 years, female, white, stage:iia, alive, 180 days
100.2
TCGA-EB-A3Y6-01A
56 years, female, white, stage:iic, alive, 126 days
100.0
TCGA-GN-A4U5-01A
61 years, female, white, stage:ib, alive, 1156 days
98.2
TCGA-HR-A5NC-01A
90 years, female, alive, 1000 days
96.6
TCGA-BF-A9VF-01A
77 years, male, white, stage:iic, alive, 440 days
95.5
TCGA-EB-A431-01A
34 years, male, white, stage:iic, alive, 568 days
94.1
TCGA-FS-A1ZN-01A
43 years, male, white, stage:iiia, dead, 730 days
90.2
TCGA-FR-A728-01A
54 years, female, white, stage:iiib, alive, 583 days
89.1
TCGA-EB-A4OY-01A
65 years, female, white, stage:iiib, alive, 977 days
88.5
TCGA-GN-A26C-01A
77 years, male, white, stage:iiic, dead, 821 days
88.3
TCGA-D9-A3Z4-01A
54 years, male, white, stage:iiic, dead, 519 days
85.5
TCGA-EB-A42Z-01A
49 years, male, asian, stage:iiic, alive, 441 days
84.6
TCGA-XV-AAZY-01A
76 years, female, white, stage:iiic, alive, 405 days
84.4
TCGA-BF-AAP6-01A
55 years, male, white, stage:iii, alive, 325 days
81.5
TCGA-BF-A5ES-01A
76 years, female, white, stage:iic, alive, 490 days
81.1
TCGA-EB-A1NK-01A
48 years, male, white, stage:iic, alive, 1039 days
80.7
TCGA-EB-A44P-01A
58 years, female, white, stage:iic, alive, 741 days
79.2
TCGA-EB-A3XD-01A
53 years, female, white, stage:iic, alive, 1160 days
79.2
TCGA-EB-A4IQ-01A
42 years, female, asian, stage:iiib, dead, 636 days
78.2
TCGA-EB-A551-01A
78 years, female, white, stage:iiic, alive, 590 days
77.6
TCGA-EB-A85I-01A
66 years, male, white, stage:iic, alive, 362 days
77.6
TCGA-YG-AA3N-01A
67 years, male, stage:iic, alive, 306 days
76.1
TCGA-ER-A2NB-01A
57 years, male, white, stage:iiib, dead, 857 days
75.8
TCGA-EB-A4OZ-01A
42 years, female, white, stage:iiic, alive, 620 days
74.4
TCGA-BF-A1Q0-01A
80 years, male, white, stage:iic, alive, 831 days
72.4
TCGA-EB-A97M-01A
66 years, male, white, stage:iic, alive, 414 days
70.8
TCGA-EB-A3HV-01A
37 years, male, white, stage:iic, alive, 39 days
70.0
TCGA-BF-A3DN-01A
81 years, female, white, stage:iiic, alive, 717 days
69.5
TCGA-XV-A9W5-01A
51 years, male, white, stage:i/ii nos, alive, 392 days
69.4
TCGA-BF-A3DM-01A
63 years, male, white, stage:iia, alive, 601 days
69.2
TCGA-FW-A5DX-01A
71 years, male, white, stage:iiic, alive, 640 days
68.4
TCGA-BF-AAP7-01A
76 years, female, white, stage:iic, alive, 318 days
68.0
TCGA-EB-A4IS-01A
77 years, male, white, stage:iib, alive, 774 days
67.8
TCGA-BF-A1PU-01A
46 years, female, white, stage:iic, alive, 387 days
67.4
TCGA-BF-AAP4-01A
61 years, male, white, stage:iic, alive, 335 days
63.7
TCGA-BF-A5ER-01A
63 years, male, white, stage:iic, alive, 327 days
63.0
TCGA-D3-A5GT-01A
43 years, male, white, stage:iiic, alive, 487 days
63.0
TCGA-EB-A5SF-01A
78 years, female, white, stage:iic, dead, 369 days
61.4
TCGA-EB-A57M-01A
56 years, male, asian, stage:iiib, dead, 472 days
59.6
TCGA-ER-A194-01A
77 years, male, white, dead, 1354 days
59.0
TCGA-BF-A3DL-01A
84 years, female, white, stage:iiib, alive, 769 days
52.8
TCGA-DA-A960-01A
73 years, male, white, stage:iib, alive, 804 days
52.7
TCGA-EB-A3XB-01A
63 years, male, white, stage:ii, alive, 796 days
52.4
TCGA-WE-A8K4-01A
85 years, male, white, stage:iib, alive, 614 days
52.1
TCGA-BF-A3DJ-01A
36 years, female, white, stage:iiib, alive, 464 days
50.1
TCGA-BF-A5EO-01A
65 years, male, white, stage:iic, alive, 703 days
49.5
TCGA-D9-A4Z5-01A
68 years, male, white, stage:iib, alive, 218 days
46.4
TCGA-EB-A6R0-01A
58 years, female, white, stage:iic, dead, 608 days
46.2
TCGA-EB-A3Y7-01A
86 years, female, white, stage:iiib, dead, 326 days
32.7
Show all
MELANOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
Antibody stainingi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off).
The Human Protein Atlas project is funded
MENU
